 Maryam Shakiba
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lithotripsy | 2 | 2023 | 49 | 0.870 |
Why?
| | Anesthesia, Spinal | 1 | 2023 | 13 | 0.830 |
Why?
| | Urolithiasis | 1 | 2023 | 10 | 0.820 |
Why?
| | Iran | 12 | 2024 | 44 | 0.700 |
Why?
| | Cardiovascular Diseases | 3 | 2024 | 2091 | 0.690 |
Why?
| | Obesity, Abdominal | 2 | 2018 | 44 | 0.580 |
Why?
| | Coronary Disease | 2 | 2018 | 373 | 0.570 |
Why?
| | Nutritional Status | 1 | 2021 | 357 | 0.560 |
Why?
| | Antibodies, Viral | 2 | 2021 | 654 | 0.530 |
Why?
| | Obesity | 3 | 2019 | 3007 | 0.470 |
Why?
| | Carbolines | 1 | 2012 | 35 | 0.360 |
Why?
| | Erectile Dysfunction | 1 | 2012 | 39 | 0.360 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 75 | 0.360 |
Why?
| | Prostatic Hyperplasia | 1 | 2012 | 41 | 0.350 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2012 | 60 | 0.330 |
Why?
| | Oral Health | 2 | 2022 | 137 | 0.310 |
Why?
| | Stroke | 1 | 2019 | 1199 | 0.310 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 144 | 0.300 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2529 | 0.290 |
Why?
| | Middle Aged | 17 | 2024 | 34658 | 0.230 |
Why?
| | Hypertension | 2 | 2013 | 1250 | 0.230 |
Why?
| | Glucose | 2 | 2023 | 1027 | 0.210 |
Why?
| | Humans | 29 | 2024 | 141284 | 0.210 |
Why?
| | Nephrostomy, Percutaneous | 2 | 2016 | 11 | 0.210 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 170 | 0.200 |
Why?
| | Bupivacaine | 1 | 2023 | 38 | 0.200 |
Why?
| | Kidney Calculi | 2 | 2016 | 44 | 0.200 |
Why?
| | Heart Failure | 1 | 2016 | 2096 | 0.190 |
Why?
| | Risk Factors | 10 | 2024 | 10490 | 0.190 |
Why?
| | Anesthetics, Local | 1 | 2023 | 101 | 0.190 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 2 | 2014 | 18 | 0.190 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 5653 | 0.190 |
Why?
| | Algorithms | 1 | 2010 | 1764 | 0.190 |
Why?
| | Fentanyl | 1 | 2023 | 123 | 0.190 |
Why?
| | Stomach Neoplasms | 1 | 2024 | 118 | 0.190 |
Why?
| | Male | 17 | 2023 | 70140 | 0.180 |
Why?
| | Mass Screening | 1 | 2010 | 1309 | 0.180 |
Why?
| | Female | 18 | 2024 | 75814 | 0.170 |
Why?
| | Ureteral Calculi | 2 | 2011 | 15 | 0.170 |
Why?
| | Publications | 1 | 2021 | 48 | 0.170 |
Why?
| | Chamomile | 1 | 2020 | 2 | 0.170 |
Why?
| | Health Education | 1 | 2024 | 360 | 0.160 |
Why?
| | Phytotherapy | 1 | 2020 | 82 | 0.160 |
Why?
| | Volatilization | 1 | 2019 | 54 | 0.150 |
Why?
| | Leiomyoma | 1 | 2019 | 56 | 0.150 |
Why?
| | Family Characteristics | 1 | 2020 | 191 | 0.150 |
Why?
| | Body Size | 1 | 2019 | 94 | 0.150 |
Why?
| | Uterine Neoplasms | 1 | 2019 | 93 | 0.150 |
Why?
| | Quality of Life | 3 | 2024 | 3024 | 0.150 |
Why?
| | Rhinitis | 1 | 2020 | 173 | 0.140 |
Why?
| | Double-Blind Method | 5 | 2020 | 1992 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 209 | 0.140 |
Why?
| | Income | 1 | 2019 | 198 | 0.140 |
Why?
| | Pain | 1 | 2023 | 779 | 0.140 |
Why?
| | Sinusitis | 1 | 2020 | 239 | 0.140 |
Why?
| | Logistic Models | 2 | 2021 | 2098 | 0.130 |
Why?
| | Public Health | 1 | 2022 | 554 | 0.130 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1311 | 0.120 |
Why?
| | Causality | 1 | 2016 | 131 | 0.120 |
Why?
| | Patient Positioning | 1 | 2016 | 71 | 0.120 |
Why?
| | Fluoroscopy | 1 | 2016 | 170 | 0.120 |
Why?
| | Supine Position | 2 | 2016 | 38 | 0.110 |
Why?
| | Prospective Studies | 6 | 2019 | 7805 | 0.110 |
Why?
| | Lipoproteins, HDL | 1 | 2015 | 78 | 0.110 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 156 | 0.110 |
Why?
| | Kidney Transplantation | 1 | 2020 | 680 | 0.110 |
Why?
| | Models, Statistical | 1 | 2018 | 669 | 0.100 |
Why?
| | Urinary Retention | 1 | 2014 | 23 | 0.100 |
Why?
| | Mastoid | 1 | 2013 | 12 | 0.100 |
Why?
| | Otologic Surgical Procedures | 1 | 2013 | 21 | 0.100 |
Why?
| | Incidence | 2 | 2020 | 2809 | 0.100 |
Why?
| | Aged | 6 | 2023 | 24836 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1380 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2020 | 851 | 0.100 |
Why?
| | Cohort Studies | 2 | 2024 | 5809 | 0.100 |
Why?
| | Survival Analysis | 1 | 2016 | 1322 | 0.100 |
Why?
| | Triglycerides | 1 | 2015 | 510 | 0.100 |
Why?
| | Blood Glucose | 1 | 2023 | 2286 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2016 | 402 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2013 | 120 | 0.090 |
Why?
| | Aged, 80 and over | 2 | 2023 | 7948 | 0.090 |
Why?
| | Papaverine | 1 | 2012 | 2 | 0.090 |
Why?
| | Renal Colic | 1 | 2012 | 4 | 0.090 |
Why?
| | Sulfonamides | 2 | 2014 | 576 | 0.090 |
Why?
| | Tadalafil | 1 | 2012 | 7 | 0.090 |
Why?
| | Albuminuria | 1 | 2013 | 185 | 0.090 |
Why?
| | Placebos | 1 | 2012 | 195 | 0.090 |
Why?
| | Prazosin | 1 | 2011 | 25 | 0.090 |
Why?
| | Flank Pain | 1 | 2011 | 9 | 0.090 |
Why?
| | Urination Disorders | 1 | 2011 | 14 | 0.090 |
Why?
| | Isosorbide | 1 | 2011 | 1 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1671 | 0.090 |
Why?
| | Otitis Media | 1 | 2013 | 168 | 0.080 |
Why?
| | Acute Pain | 1 | 2012 | 54 | 0.080 |
Why?
| | Adult | 9 | 2023 | 39319 | 0.080 |
Why?
| | Prone Position | 1 | 2010 | 27 | 0.080 |
Why?
| | Weight Loss | 1 | 2016 | 794 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2020 | 11216 | 0.080 |
Why?
| | Analgesics | 1 | 2012 | 231 | 0.080 |
Why?
| | Anthropometry | 1 | 2010 | 208 | 0.080 |
Why?
| | Institutionalization | 1 | 2009 | 12 | 0.080 |
Why?
| | Tooth Diseases | 1 | 2009 | 13 | 0.080 |
Why?
| | Mouth Diseases | 1 | 2009 | 46 | 0.080 |
Why?
| | Chronic Pain | 1 | 2013 | 281 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4080 | 0.070 |
Why?
| | Stents | 1 | 2011 | 535 | 0.060 |
Why?
| | Pain Measurement | 3 | 2013 | 555 | 0.060 |
Why?
| | Neoplasms | 1 | 2020 | 2731 | 0.060 |
Why?
| | Chronic Disease | 3 | 2020 | 1807 | 0.060 |
Why?
| | Body Mass Index | 3 | 2019 | 2390 | 0.050 |
Why?
| | Kidney | 1 | 2010 | 1482 | 0.050 |
Why?
| | Dentistry | 1 | 2022 | 9 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2014 | 2831 | 0.040 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 526 | 0.040 |
Why?
| | Administration, Intranasal | 1 | 2020 | 92 | 0.040 |
Why?
| | Cities | 1 | 2021 | 137 | 0.040 |
Why?
| | Bias | 1 | 2021 | 208 | 0.040 |
Why?
| | Survivors | 1 | 2024 | 501 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 81 | 0.040 |
Why?
| | Lipids | 1 | 2024 | 686 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3577 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2012 | 1043 | 0.040 |
Why?
| | Age Factors | 2 | 2019 | 3295 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2019 | 360 | 0.030 |
Why?
| | Adolescent | 3 | 2014 | 22116 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2024 | 16447 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2904 | 0.030 |
Why?
| | Waist Circumference | 1 | 2016 | 134 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5948 | 0.030 |
Why?
| | Ultrasonography | 1 | 2019 | 765 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1610 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 1395 | 0.030 |
Why?
| | Premenopause | 1 | 2015 | 120 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 316 | 0.030 |
Why?
| | Varicocele | 1 | 2014 | 10 | 0.030 |
Why?
| | Scrotum | 1 | 2014 | 26 | 0.030 |
Why?
| | Operative Time | 1 | 2014 | 158 | 0.020 |
Why?
| | Herniorrhaphy | 1 | 2014 | 76 | 0.020 |
Why?
| | Postmenopause | 1 | 2015 | 369 | 0.020 |
Why?
| | Postoperative Period | 1 | 2013 | 359 | 0.020 |
Why?
| | Suppositories | 1 | 2012 | 3 | 0.020 |
Why?
| | Diclofenac | 1 | 2012 | 15 | 0.020 |
Why?
| | Time Factors | 2 | 2014 | 6951 | 0.020 |
Why?
| | Hematuria | 1 | 2011 | 11 | 0.020 |
Why?
| | Nocturia | 1 | 2011 | 8 | 0.020 |
Why?
| | Placebo Effect | 1 | 2011 | 25 | 0.020 |
Why?
| | Parasympatholytics | 1 | 2011 | 11 | 0.020 |
Why?
| | Celecoxib | 1 | 2011 | 39 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 418 | 0.020 |
Why?
| | Methylprednisolone | 1 | 2011 | 64 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1057 | 0.020 |
Why?
| | Child | 1 | 2010 | 22390 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2011 | 175 | 0.020 |
Why?
| | Stomatitis, Denture | 1 | 2009 | 1 | 0.020 |
Why?
| | Tongue, Fissured | 1 | 2009 | 1 | 0.020 |
Why?
| | Burning Mouth Syndrome | 1 | 2009 | 5 | 0.020 |
Why?
| | Mouth Floor | 1 | 2009 | 7 | 0.020 |
Why?
| | Xerostomia | 1 | 2009 | 16 | 0.020 |
Why?
| | Mouth, Edentulous | 1 | 2009 | 10 | 0.020 |
Why?
| | Varicose Veins | 1 | 2009 | 16 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1505 | 0.020 |
Why?
| | Tongue | 1 | 2009 | 81 | 0.020 |
Why?
| | Periodontal Diseases | 1 | 2009 | 59 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1005 | 0.020 |
Why?
| | Atrophy | 1 | 2009 | 195 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 350 | 0.020 |
Why?
| | Colon | 1 | 2010 | 295 | 0.020 |
Why?
| | Dental Caries | 1 | 2009 | 173 | 0.020 |
Why?
| | Nursing Homes | 1 | 2009 | 171 | 0.020 |
Why?
| | Pyrazoles | 1 | 2011 | 482 | 0.020 |
Why?
| | Young Adult | 2 | 2014 | 13727 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2929 | 0.010 |
Why?
| | Risk Assessment | 1 | 2013 | 3522 | 0.010 |
Why?
| | Sex Factors | 1 | 2009 | 2055 | 0.010 |
Why?
| | Prevalence | 1 | 2009 | 2795 | 0.010 |
Why?
|
|
Shakiba's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|